EHA 2019: Highly effective combination for initial therapy for young, fit CLL patients

Matthew Davids | EHA 2019 | Juni 18, 2019

Speaker: Matthew Davids

The rate of bone marrow minimal residual diseaseinduced byibrutinibin combination with fludarabine, cyclophosphamide, rituximabisthe highest ever reported for a regimen treating a population of CLL patients unrestricted by prognostic marker status.  The safety profile of the combination therapy was generally favorable, with typical toxicities of ibrutinib and fludarabine, cyclophosphamideand rituximabobserved, and no additional toxicities discernable with the combination.